13.02

2.47% -0.33

After Hours: 13.01 -0.010 -0.08%

Wave Life Sciences Ltd (WVE)

Overview News Price History Option Chain Financials Why WVE Down? Discussions Forecast

Wave Life Sciences Ltd stock is traded at $13.02, with a volume of 2.83M. It is down -2.47% in the last 24 hours and up +2.68% over the past month. WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Previous Close:

$13.35

Open:

$13.42

24h Volume:

2.83M

Relative Volume:

0.43

Market Cap:

$2.45B

Revenue:

$42.73M

Net Income/Loss:

$-204.38M

P/E Ratio:

-10.74

EPS:

-1.2124

Net Cash Flow:

$-189.73M

1W Performance:

-0.76%

1M Performance:

+2.68%

6M Performance:

+86.80%

1Y Performance:

+26.78%

1-Day Range:

$12.58

$13.65

1-Week Range:

$12.58

$14.32

52-Week Range:

$5.28

$21.73

Wave Life Sciences Ltd Stock (WVE) Company Profile

Name

Wave Life Sciences Ltd

Sector

Healthcare (1116)

Industry

Biotechnology (621)

Phone

617-949-2900

Address

7 STRAITS VIEW, SINGAPORE

Employee

317

Twitter

@WAVELifeSci

Next Earnings Date

2025-03-04

Latest SEC Filings

WVE's Discussions on Twitter

Compare WVE vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
WVE Wave Life Sciences Ltd	13.02	2.51B	42.73M	-204.38M	-189.73M	-1.2124
VRTX Vertex Pharmaceuticals Inc	469.34	121.46B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	745.77	78.93B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	700.45	43.87B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	313.41	42.07B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	284.05	31.65B	5.36B	287.73M	924.18M	2.5229

Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-05-26	Initiated	BofA Securities	Buy
Dec-12-25	Reiterated	Wedbush	Outperform
Dec-09-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Oct-20-25	Initiated	Wells Fargo	Overweight
Aug-04-25	Initiated	Canaccord Genuity	Buy
Jul-28-25	Initiated	Oppenheimer	Outperform
Jul-16-25	Initiated	Citigroup	Buy
Jun-11-25	Resumed	Raymond James	Outperform
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Apr-08-25	Initiated	Wedbush	Outperform
Feb-25-25	Initiated	Jefferies	Buy
Oct-16-24	Upgrade	Raymond James	Outperform → Strong Buy
Sep-27-24	Resumed	JP Morgan	Overweight
Sep-19-24	Initiated	B. Riley Securities	Buy
Sep-09-24	Initiated	JP Morgan	Overweight
May-15-24	Initiated	Wells Fargo	Overweight
Dec-19-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Raymond James	Outperform
May-24-23	Downgrade	Jefferies	Buy → Hold
Dec-15-20	Resumed	H.C. Wainwright	Buy
Oct-23-20	Initiated	RBC Capital Mkts	Sector Perform
Dec-31-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-01-19	Initiated	Guggenheim	Buy
Jul-15-19	Initiated	Cowen	Market Perform
Apr-17-19	Reiterated	H.C. Wainwright	Buy
Aug-07-18	Initiated	Stifel	Buy
Jul-23-18	Initiated	H.C. Wainwright	Buy
Mar-19-18	Reiterated	Mizuho	Buy
Feb-15-17	Initiated	H.C. Wainwright	Buy
Nov-10-16	Resumed	Leerink Partners	Outperform
Dec-07-15	Initiated	JMP Securities	Mkt Outperform
Dec-07-15	Initiated	Jefferies	Buy
Dec-07-15	Initiated	Leerink Partners	Outperform
Dec-07-15	Initiated	Sun Trust Rbsn Humphrey	Buy

View All

Wave Life Sciences Ltd Stock (WVE) Latest News

Mar 12, 2026

Discipline and Rules-Based Execution in WVE Response - Stock Traders Daily

Mar 12, 2026

Mar 11, 2026

Dynamic SXSW panel reshapes obesity treatment narrative, WAVE Life Sciences asserts - Traders Union

Mar 11, 2026

Mar 10, 2026

Canaccord Genuity Boosts Price Target for WAVE Life Sciences (WV - GuruFocus

Mar 10, 2026

WAVE Life Sciences Stock: A Deep Dive Into Analyst Perspectives (11 Ratings) - Benzinga

Mar 10, 2026

WAVE Life Sciences (NASDAQ:WVE) Given New $52.00 Price Target at Canaccord Genuity Group - MarketBeat

Mar 10, 2026

Mar 09, 2026

Wave Life Sciences to present WVE-006 trial data at ATS - Investing.com Nigeria

Mar 09, 2026

Mar 08, 2026

Wave Life Sciences (WVE) Is Down 5.8% After Wider Losses And WVE-006 Accelerated Approval PushWhat's Changed - simplywall.st

Mar 08, 2026

Mar 07, 2026

Wave Life Sciences (WVE) Valuation Check After New RNA Editing And Obesity Trial Updates - simplywall.st

Mar 06, 2026

Wedbush Forecasts Strong Price Appreciation for WAVE Life Sciences (NASDAQ:WVE) Stock - MarketBeat

Mar 06, 2026

Wave Life Sciences (WVE) Anticipates Positive Developments with WVE-007 Data - GuruFocus

Mar 06, 2026

Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference - Sahm

Mar 06, 2026

Wave Life Sciences to present WVE-006 trial data at ATS By Investing.com - Investing.com Canada

Mar 06, 2026

Mar 05, 2026

Wave Life Sciences announces acceptance of late-breaking oral presentation on Wve-006 for alpha-1 antitrypsin deficiency at the American Thoracic Society international conference - marketscreener.com

Mar 05, 2026

Q1 EPS Forecast for WAVE Life Sciences Raised by Analyst - MarketBeat

Mar 05, 2026

Mar 04, 2026

FY2029 Earnings Forecast for WVE Issued By HC Wainwright - MarketBeat

Mar 04, 2026

Mar 03, 2026

Wave Life Sciences Obesity Proof Of Concept Sparks Focus On Pipeline Upside - simplywall.st

Mar 03, 2026

WVE SEC FilingsWave Life Scienc 10-K, 10-Q, 8-K Forms - Stock Titan

Mar 03, 2026